POSSIBILITIES OF USE OF THE MODERN ANTIHISTAMINE MEDICINES IN THERAPY OF PATIENTS WITH ALLERGIC RHINITIS

Allergic rhinitis as one of the most common non-infectious respiratory inflammatory diseases is a global public health problem. The course of allergic rhinitis, its effect on the pathology of other organs and systems, the likelihood of complications and many other aspects of this pathology are largely determined by timely diagnosis and adequate treatment. At the heart of the pathogenesis of allergic rhinitis is the immediate allergic reaction. Histamine is the most important biogenic amine, the physiological regulator of the activity of various cells and systems and one of the main mediators of allergic reactions of immediate type. In the treatment of allergic rhinitis, one of the key places is occupied by antihistamines. One of such highly effective modern antihistamines is levocetirizine – a blocker of H1 histamine receptors of the second generation. Leveltzetirizine affects the histamine-dependent stage of allergic reactions, reduces vascular permeability and eosinophil migration, limits the release of inflammatory mediators, significantly influences the formation of edema of the tissues and the production of mucus, prevents development and greatly facilitates the course of the allergic reaction, has antiexudative, antipruritic and anti-inflammatory effects, and a pronounced ability to eliminate nasal obstruction in patients with seasonal allergic rhinitis. The drug levocetirizine Allerway®, bioequivalent to the original drug, is of definite interest to physicians of various specialties.

1. Крюков А.И., Туровский А.Б., Бондарева Г.П., Семкина О.В. Принципы лечения аллергического ринита. Медицинский совет, 2013, 7: 42-47.

2. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy, 2007, 62(suppl85): 9-16.

3. Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy, 2007, 62(suppl 85): 17-25.

4. Аллергология и иммунология. Национальное руководство. АСМОК. РААКИ. Гэотар-Медиа. 2009: 245-250.

5. Schoenwetter WF, Dupclay L, Appajosyula S et al. Economic impact and quality of life burden of allergic rhinitis. Curr Med Res Opin, 2004, 20: 305-317.

6. Meltzer EO, Nathan R, Derebery J et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc, 2009, 30: 244-254.

7. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc, 2007, 28: 3-9.

8. Blaiss MS. Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc, 2007, 29: 1-6.

9. Meltzer EO, Blaiss MS, Derebery MJ et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol, 2009, 124: S43-S70.

10. Никифорова Г.Н., Волкова К.Б., Свистушкин В.М. Место и значение современных антигистаминных препаратов в лечении аллергического ринита. РМЖ, 2015, 23: 1395-1398.

11. Дробик О.С. Аллергический ринит: современные подходы к диагностике и терапии. Эффективная фармакотерапия, 2014, 29: 54-59.

12. Bousquet J. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy, 2008, Apr, 63(Suppl 86): 8-160.

13. Jenerowicz D, Silny W, Dańczak-Pazdrowska A, Polańska A, Osmola-Mańkowska A, Olek-Hrab K. Environmental factors and allergic diseases. Ann. Agric Environ Med, 2012, 19(3): 475-81.

14. Пухлик С.М., Дедикова И.В. Терапевтические возможности антигистаминных препаратов при фармакологической коррекции симптомов аллергического ринита. Оториноларингология. Восточная Европа, 2014, 4(17): 85-90.

15. Brozek JL, Bousquet J et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol, 2010 Sep, 126(3): 466-76.

16. Mullol J, Valero A, Alobid I, Bartra J, Navarro AM, Chivato T, Khaltaev N, Bousquet J. Allergic Rhinitis and its Impact on Asthma update (ARIA 2008). The perspective from Spain. J Investig. Allergol. Clin. Immunol., 2008, 18(5): 327-34.

17. Трищук Н.М., Книженко И.Б., Жаботинская Н.В., Кубата С.Г. Современные подходы к решению проблемы аллергического ринита. Сучасні проблеми фармакотерапії і призначення лікарських засобів. Матеріали XXX Всеукраїнської науковопрактичної конференції з міжнародною участю. 23 травня 2013 року. м. Харків. 302-310.

18. Derebery J, Meltzer E, Nathan RA et al. Rhinitis symptoms and comorbidities in theUnited States: burden of rhinitis in America survey. Otolaryngol. Head Neck Surg., 2008, 139(2): 198-205.

19. Вельтищев Д.Ю., Ковалевская О.Б., Серавина О.Ф. Стресс и модус предрасположения в патогенезе расстройств депрессивного спектра. Психические расстройства в общей медицине, 2008, 2: 34-37.

20. Трусова О.В., Коростовцев Д.С. Левоцетиризин (Ксизал). Характеристика препарата и опыт клинического применения. Аллергология, 2006, 2: 25-31.

21. Щербак И.Б. Акценты антигистаминной терапии: левоцетиризин. Врачу-практику, 2012, 3(89), V/VI.

22. Ciprandi G, Cirillo IG, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Eur. Ann. Allergy Clin. Immunol., 2005, 37(1): 25-29.

23. Day JH, Ellis AK, Rafeiro E. Levocetirizine: a new selective H1 receptor antagonist for use in allergic disorders. Drugs Today (Barc), 2004, 40(5): 415-421.

24. Nettis E, Calogiuri GF, Di Leo E et al. Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria. J. Asthma Allergy, 2008, 2: 17-23.

25. Астафьева Н.Г., Гамова И.В., Удовиченко Е.И., Перфилова И.А. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Клиническая фармакология, 2010, 5: 56-61.

26. Frossard N, Strolin-Benedetti M, Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br. J. Clin. Pharmacol., 2008, 65(2): 172-179.

27. Gillman S, Gillard M, Benedetti MS. The Concept of Receptor Occupancy to predict clinical Efficacy: a Comparison of second Generation H1-antihistamines. Allergy Asthma Proc, 2009, 30: 366-376.

28. Gillard M et al. Histamine H1-receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res, 2005, 54: 367-369.

29. Benedetti MS et al. Evaluation of the receptor occupancy by desloratadine and levocetirizine in allergic subjects. World Allergy Org. J., 2007, Abs 514: S163-S164.

30. Lipworth BJ, White PS. Allergic inflammation in the unified airway: start with the nose. Thorax, 2000, 55(10): 878-881.

31. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and odulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin. Exp. Allergy, 2004, 34(6): 958-964.

32. De Blic J, Wahn U, Billard E et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr. Allergy Immunol, 2005, 16(3): 267-275.

33. Simons FE. Early Prevention of Asthma in Atopic Children Study Group H1-antihistamine treatment in young atopic children: effect on urticaria. Ann. Allergy Asthma Immunol, 2007, 99(3): 261-266.

34. Bachert C. Clinical and Experimental Allergy Review, 2005, 5: 40-43.

35. Bousquet J et al. for XPERT study group. Allergy, 2005, 60(6): 788-794.

36. Pasquali M, Baiardini I, Rogkakou A et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin. Exp. Allergy, 2006, 36(9): 1161-1167.

37. Таха Т.В. Применение левоцетиризина в лечении зудящих дерматозов. РМЖ, 2009, 6: 402.

38. Отчет о результатах клинического исследования сравнительной фармакокинетики и биоэквивалентности лекарственного препарата Левоцетиризин («Д-р Редди’с Лабораторис Лтд.», Индия) и Ксизал® (левоцетиризин) производства «ЮСБ Фаршим С.А.» (Швейцария). 2015.

39. Инструкция по медицинскому применению препарата Аллервэй®.